Enimmune Corporation (TPEX:6564)

Market Cap	1.31B -30.4%
Revenue (ttm)	42.23M -16.9%
Net Income	-164.74M
EPS	-2.22
Shares Out	72.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,554
Average Volume	142,516
Open	17.75
Previous Close	17.75
Day's Range	17.40 - 18.15
52-Week Range	14.65 - 27.10
Beta	0.39
RSI	49.57
Earnings Date	Apr 17, 2026

About Enimmune

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6564

Financial Performance

In 2024, Enimmune's revenue was 39.92 million, a decrease of -8.23% compared to the previous year's 43.49 million. Losses were -157.55 million, -29.59% less than in 2023.